Introduction
Lokivetmab is a caninized anti-canine interleukin-31 (IL-31) monoclonal antibody (mAb) that binds to and neutralizes the soluble inflammatory mediator IL-31 in dogs. 1, 2 Field and laboratory studies show IL-31 is a critical cytokine involved in pruritus in dogs with atopic dermatitis (AD). 1 The current report details results of a randomized clinical trial that evaluated the safety of lokivetmab in dogs with AD under field conditions where there were minimal restrictions on co-morbidities and no restrictions on concomitant medications.
Materials and methods
The study was conducted in support of product registration by the United States Department of Agriculture. The protocol was reviewed by and approved before study initiation by the Zoetis Ethical Review Board. The owners gave written informed consent for each dog to participate in the study.
Dogs were client-owned of any age and body weight, overall healthy, apart from AD, based on the initial (Day 0) physical examination and were diagnosed with AD based on clinical signs and compatible history, according to the veterinarian. Exclusion criteria included dogs with evidence of malignant neoplasia or immune suppression (e.g. hyperadrenocorticism) and lactating bitches or dogs intended for use as breeding animals.
Enrolled dogs were randomized to treatment with lokivetmab or placebo in a 2:1 ratio at each clinic using SAS v9.3 (SAS Institute Inc.; Cary, NC, USA). Blocking was based on order of enrolment within clinic. Dog was the experimental unit. Dog owners, laboratory personnel, clinicians and all site personnel, with the exception of the treatment dispenser, were masked to treatment group assignments. The treatment dispenser utilized a treatment randomization file that was unique to the site to determine the treatment group assignment, drew up the correct dose of treatment into a syringe and then provided it to study personnel for administration.
Lokivetmab was provided in ready-to-use one mL single-use (no preservative) vials containing 10, 20, 30 or 40 mg/mL in a histidine buffer. Dogs in the placebo group were given the same volume as dogs in the lokivetmab group; the placebo was identical in appearance to the lokivetmab and contained all of the same excipients except for lokivetmab. Placebo and lokivetmab were stored refrigerated (2-8°C) before use. Following randomization, dogs were assigned to receive either placebo or lokivetmab (1.0-3.3 mg/kg) subcutaneously on days 0 and 28 (AE3 days). A dose of 1.0 mg/kg represented a nominal dose.
Baseline data (demographic, physical examination) were collected on enrolment at Day 0. Owners returned dogs to the clinic on days 28(AE3) and 42(AE3) for physical examination. Clinicians recorded adverse events 3 reported by owners or identified on physical examination throughout the study. Blood samples [complete blood count, serum chemistry, anti-drug antibodies (ADAs) and lokivetmab concentrations] and urine samples for urinalysis and urine protein creatinine ratio were collected on days 0 and 28 (before dosing) and Day 42. The samples were sent to one laboratory (Heska Corp.; Loveland, CO, USA). Serum samples at each time point were analysed for lokivetmab and ADAs using validated methods at Zoetis Inc., Kalamazoo, MI, USA.
Data were summarized using SAS v9.3 (SAS Institute). No hypothesis testing was conducted.
For each continuous haematology and serum chemistry measure, summary statistics (mean, median, standard deviation, minimum and maximum) were calculated by treatment and time point. Frequencies of dogs reported to experience at least one adverse event were summarized by clinical sign for all unique terms. Frequencies of dogs receiving each concomitant medication over the course of the study were summarized.
Results
Two hundred and forty five dogs were enrolled from 14 veterinary clinics (Table 1 ). All enrolled dogs were included in the summaries. The same percentage (1.2%) of cases in both treatment groups were withdrawn from study or lost to follow-up before Day 42. Table 2 provides a comparison of adverse events that occurred in >2% of lokivetmab-treated dogs. A similar proportion of vomiting, anorexia, lethargy and diarrhoea adverse events in both groups resolved spontaneously or with supportive care. Adverse events involving skin infection (e.g. pyoderma) were followed post-study until resolution or considered by the clinician to be a chronic condition. Discomfort associated with injection persisting beyond the immediate post-injection period was reported once and involved scratching at the site of lokivetmab administration for 15 min following the first dose only. There were no hypersensitivity reactions (e.g. wheals, vomiting) immediately post-dosing and no reports of injection site reactions (e.g. injection site swelling or redness). The remaining adverse events occurred in <2.0% of the lokivetmab-treated group. Arithmetic mean values for all clinical pathology analytes in both treatment groups fell within the laboratory's normal reference ranges at all visits (days 0, 28 and 42) except serum alkaline phosphatase (placebo group) which was slightly above reference range throughout the study.
Two dogs in each treatment group showed serious adverse events. The first case was a 4-year-old neutered female English cocker spaniel; significant findings on Day 0 before treatment with lokivetmab included fever (39.8°C), mild regenerative anaemia, slight polychromasia and three nucleated red blood cells per 100 white blood cells; platelets were clumped and an accurate count was, therefore, unavailable. Treatment with cefpodoxime proxetil was initiated (Day 8) to treat a cough associated with tracheobronchitis of one day duration. Immune-mediated haemolytic anaemia and immune-mediated thrombocytopaenia were diagnosed (Day 12); remission was achieved by Day 43 with immunosuppressive treatment. Serious adverse events in the remaining three dogs included a placebo-treated dog diagnosed with diabetes mellitus after initiating a corticosteroid and two dogs, one placebo-treated and one lokivetmab-treated, that had preexisting conditions (well-controlled hypoadrenocorticism and moderate regenerative anaemia, respectively) and were diagnosed with lymphoma while on study.
Of the >200 concomitant medications administered during this study, those most frequently used (i.e. ≥6% of lokivetmab-treated group) are summarized in Supplementary Table 1 .
Four (2.5%) of the lokivetmab-treated dogs were categorized as having treatment-induced immunogenicity; anti-lokivetmab titres in these dogs were <10 at Day 0, remained low on Day 28 (<10 to 10) and increased on Day 42 (32-315). Average day 28 and 42 serum lokivetmab concentrations were~90% lower than the remaining treated animals.
Discussion
The lack of restrictions on concomitant medications in the current trial likely contributed to a similar proportion of placebo-and lokivetmab-treated dogs completing the study, thus allowing a direct comparison of adverse event frequencies. The cases with serious adverse events reported would not have been eligible to enrol in a traditionally designed field efficacy study with restrictions on concomitant conditions at enrolment, and where corticosteroids and systemic antibiotics are not permitted during study or shortly before enrolment. There were no clinically apparent adverse interactions between lokivetmab and any of the concomitantly administered medications, although this study was not designed specifically to detect such interactions. Xenobiotic metabolizing enzymes, such as cytochrome P450 enzymes, are not involved in elimination of mAbs; therefore, metabolic drug-drug interactions, caused by inhibition or induction of cytochrome P450 enzymes, are not expected. 4 However, other types of interactions are possible, notably cytokine-mediated changes in expression of drug-metabolizing enzymes. 5 In chronic inflammatory diseases, elevated levels of cytokines such as IL-6 and TNFa lead to downregulation of cytochrome P450 enzymes. 5, 6 Treatment with a mAb that blocks the action of proinflammatory cytokines can result in normalization of cytochrome P450 levels and thus affect the levels of other concomitantly administered small molecule drugs. 7 If pro-inflammatory cytokines downregulate cytochrome P450 enzymes in dogs with AD, a decrease in these cytokines following administration of a therapeutic mAb could be expected to lead to a decrease in circulating concentrations of concomitantly administered CYP450-metabolized drugs (e.g. ciclosporin), although such an effect is most relevant for drugs with a narrow therapeutic range (e.g. antineoplastic drugs).
Lokivetmab is a "caninized" monoclonal antibody; 2 such speciation decreases immunogenicity in the target species, 8 even though all therapeutic mAbs remain immunogenic to some extent. 9 ADAs may bind to therapeutic mAbs leading to neutralization or increased clearance and potentially result in decreased efficacy. 9, 10 ADAs have been associated with a higher risk of hypersensitivity reactions 10 although such reactions have not been observed in dogs treated with lokivetmab in laboratory or clinical field trials thus far.
The current study was not designed to compare safety of doses within the range administered (e.g. 1.0 mg/kg compared to 3.3 mg/kg). However, laboratory dog studies identified no treatment-related adverse effects following repeat administration of lokivetmab at the highest dose tested (10 mg/kg) (data on file).
Results of this study demonstrated that under field conditions two consecutive monthly doses of lokivetmab (1.0-3.3 mg/kg) were safe in a diverse population of 162 client-owned dogs, diagnosed with AD, based on observed adverse events and clinical pathology results. Further studies are needed to evaluate the safety of lokivetmab following long-term use in dogs with AD.
Supporting Information
Additional Supporting Information may be found in the online version of this article. Table S1 . Concomitant medications and therapies administered at least once to at least 6% of lokivetmabtreated group over the course of the 42 day study.
R esum e Contexte -Le lokivetmab (ZTS-00103289) est un anticorps monoclonal anti-IL-31 canin qui a montr e son efficacit e dans la r eduction du prurit associ e a la dermatite atopique (AD) chez le chien dans les essais de terrain.
Hypoth eses/Objectifs -Cette etude evalue l'innocuit e du lokivetmab dans un essai contrôl e contre placebo, randomis e, en double aveugle, chez des chiens de propri etaires atteints de dermatite atopique avec des restrictions minimales sur les traitements concomitants et les comorbidit es. 
Resumen
Introducci on -Lokivetmab (ZTS-00103289) es un anticuerpo monoclonal anti-canino caninizado frente a IL-31 que ha demostrado eficacia en la reducci on del prurito asociado con la dermatitis at opica (AD) en perros en pruebas de campo. Hip otesis/Objetivos -Este estudio evalu o la seguridad de lokivetmab en un estudio doble ciego, al azar, controlado con placebo en perros de propietarios privados con AD con restricciones m ınimas acerca de medicamentos concomitantes y otras enfermedades conjuntas. Animales -Los m edicos veterinarios en 14 cl ınicas veterinarias admitieron perros de propietarios privados (n = 245) con AD cr onica. M etodos -Los perros fueron asignados al azar en una proporci on de 2: 1 para recibir lokivetmab (1,0 a 3,3 mg / kg) por v ıa subcut anea o placebo administrado en los d ıas 0 y 28. Los veterinarios examinaron los perros, la sangre y la orina recogidos para la evaluaci on de la patolog ıa cl ınica y la inmunogenicidad (d ıas 0, 28 y 42). Resultados -No hubo reacciones de hipersensibilidad inmediata (por ejemplo, ronchas, v omitos). Se observ o malestar tras la administraci on en un 5,1% de los perros que fue similar en frecuencia y gravedad entre lokivetmab y los grupos tratados con placebo. Prurito fue reportado como un efecto adverso durante el estudio con menor frecuencia en el grupo tratado con lokivetmab (4,9% y 19,3%, respectivamente). Aparte de esto, los efectos adversos se produjeron con una frecuencia similar entre los grupos de tratamiento. No hubo diferencias cl ınicamente importantes entre los grupos en los resultados de patolog ıa cl ınica. Inmunogenicidad inducida por el tratamiento se encontr o en 2,5% de los perros tratados con lokivetmab. Una amplia variedad de medicamentos concomitantes fueron utilizados durante el estudio sin interacciones adversas cl ınicamente aparentes. Conclusiones e importancia cl ınica -En una poblaci on diversa de 162 perros de propietarios privados con un diagn ostico cl ınico de la AD, el tratamiento con dos dosis mensuales de lokivetmab fue seguro, basado en los eventos adversos observados y los resultados de patolog ıa cl ınica durante un periodo de 42 d ıas.
Zusammenfassung
Hintergrund -Lokivetmab (ZTS-00103289) ist ein caninisierter anti-Hunde IL-31 monoklonaler Antik€ orper, der bei der Reduzierung des Juckreizes, der durch eine atopische Dermatitis (AD) bei Hunden in Feldstudien bedingt war, Wirksamkeit gezeigt hat. Hypothese/Ziele -Diese Studie evaluierte die Sicherheit von Lokivetmab in einer randomisierten, doppelblinden, Plazebo-kontrollierten Studie mit Hunden in Privatbesitz mit AD mit minimalen Einschr€ ankungen von begleitenden Medikamenten und Begleiterkrankungen. Tiere -KlinikerInnen in 14 Veterin€ arkliniken nahmen Privathunde (n = 245) mit chronischer AD in die Studie auf. Methoden -Die Hunde wurden zuf€ allig im Verh€ altnis 2:1 eingeteilt, um entweder Lokivetmab (1,0-3,3 mg/ kg) oder Plazebo, welches subkutan verabreicht wurde, an den Tagen 0 und 28 zu erhalten. Die KlinikerInnen untersuchten die Hunde und nahmen Blut-und Urinproben, um die klinische Pathologie und die Immunogenit€ at (an den Tagem 0, 28 und 42) zu erfassen. Ergebnisse -Es bestanden keine Immunreaktionen vom Soforttyp (z.B. Blasen, Vomitus). Bei 5,1% der Hunde bestand ein Unbehagen bei der Verabreichung, welches € ahnlich in Frequenz und Schweregrad in ocorreram em frequência similar entre os dois grupos. Não houve nenhuma alterac ßão significativa entre os grupos nos resultados de patologia cl ınica. Imunogenicidade induzida pelo tratamento foi encontrada em 2,5% dos cães tratados com lokivetmab. Um ampla variedade de medicac ßões concomitantes foi usada sem interac ßões adversas aparentes. Conclusões e importância cl ınica -O tratamento com lokivetmab em duas aplicac ßões mensais em 162 cães com DA crônica clinicamente diagnosticada foi seguro, baseado em reac ßões adversas e an alises cl ıni-cas, em um per ıodo de 42 dias.
